Avatrombopag

Product NameAvatrombopag
CAS570406-98-3
CBNumberCB72522099
MFC29H34Cl2N6O3S2
MW649.65
EINECS1312995-182-4
MDL NumberMFCD18633249
MOL File570406-98-3.mol
MSDS FileSDS

Chemical Properties

Density	1.440
solubility	DMSO:27.33(Max Conc. mg/mL);42.07(Max Conc. mM)
form	A crystalline solid
pka	3.04±0.70(Predicted)
FDA UNII	3H8GSZ4SQL
NCI Drug Dictionary	crenolanib besylate
ATC code	B02BX08

Safety

Symbol(GHS)

Signal word

Danger

Hazard statements

H314

Precautionary statements

P280-P305+P351+P338-P310

NFPA 704:

	0
2		0

Avatrombopag Price

Product number	Packaging	Price	Product description	Buy
ChemScene CS-3397	5mg	$420	Avatrombopag	Buy
American Custom Chemicals Corporation API0008153	5MG	$502.93	AKR-501 95.00%	Buy
ChemScene CS-3397	10mg	$600	Avatrombopag	Buy
ChemScene CS-3397	50mg	$1800	Avatrombopag	Buy
ChemScene CS-3397	100mg	$2520	Avatrombopag	Buy

Avatrombopag Chemical Properties,Usage,Production

Description

Avatrombopag is a medication that used for certain conditions that lead to thrombocytopenia (low platelets) such as thrombocytopenia associated with chronic liver disease in adults who are to undergo a planned medical or dental procedure.It was the third thrombopoietin receptor agonist approved for the treatment of immune thrombocytopenia and the first approved to treat periprocedural thrombocytopenia in patients with chronic liver disease (thereby providing an alternative to blood transfusions for these patients). Avatrombopag was approved for medical use in the United States in 2018, and in the European Union in 2019.

Uses

Avatrombopag is used to treat thrombocytopenia (a low number of platelets [type of blood cell needed for blood clotting]) in people with chronic (ongoing) liver disease. It is also used to treat thrombocytopenia in people with chronic immune thrombocytopenia (ITP; an ongoing condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood).

Mechanism of action

Avatrombopag is in a class of medications called thrombopoietin (TPO) receptor agonists. It works by causing the body to produce more platelets.

target

TPO receptor

IC 50

IC 50 value is 3.3 nM.

Avatrombopag synthesis

570407-10-2

570406-98-3

Preparation Products And Raw materials

Raw materials

4-(4-Chloro-2-thienyl)-2-thiazolamine

Avatrombopag Supplier

Global(116)Suppliers

Region

China 103 India 4 United Kingdom 1 United States 8

Clear All Done

Supplier	Tel	Email	Country	ProdList	Advantage
Zison Pharmaceutical (Shandong) Co., Ltd.	+86-0086-531-88259693 +86-18660188356	maguanglei@zisonpharm.com	China	53	58
Jewim Pharmaceutical (Shandong) Co., Ltd.	+86-15552509998 +86-15621883869	liutf@jewim.com.cn	China	251	58
Jiangsu shring Biopharma Co., Ltd.	+8613372282299	sales@shringchem.com	China	3545	58
Zhejiang ZETian Fine Chemicals Co. LTD	18957127338	stella@zetchem.com	China	2141	58
BOC Sciences	+1-631-485-4226	inquiry@bocsci.com	United States	19553	58
CONIER CHEM AND PHARMA LIMITED	+8618523575427	sales@conier.com	China	49390	58
career henan chemical co	+86-0371-86658258 15093356674;	factory@coreychem.com	China	29826	58
Dideu Industries Group Limited	+86-29-89586680 +86-15129568250	1026@dideu.com	China	29016	58
Zhejiang J&C Biological Technology Co.,Limited	+1-2135480471 +1-2135480471	sales@sarms4muscle.com	China	10523	58
Jinan Ande Pharmaceutical Co.,Ltd.	+8613256107535	andepharm@163.com	CHINA	221	58

Avatrombopag: Pharmacodynamic Properties, Therapeutic Efficacy, Dosage and Administration
Avatrombopag, a thrombopoietin receptor agonist, boosts platelet production without affecting function, offering potential treatment for ITP and CLD-associated thrombocytopenia.
Apr 1，2024
The synthesize method of Avatrombopag
Avatrombopag is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.
Dec 22，2023

Avatrombopag: mechanism of action, pharmacokinetics and clinical applications

Avatrombopag is a medication that treats thrombocytopenia by mimicking thrombopoietin, increasing platelet count through receptor activation and signal pathways.

Sep 26，2023